Markers of PI3K/Akt, ER & AR pathways and Ki67 expression in relation to tamoxifen outcome in ER plus breast cancer

被引：0
|
作者：
Campbell, C.
Mathew, J.
Ellis, I.
Finlay, P.
Green, A.
Bradbury, I.
Borgquist, S.
Elebro, K.
Politz, O.
Haegebarth, A.
Gee, J. M.
Robertson, J. F.
机构：
[1] Frontier Sci Scotland, Inverness, Scotland
[2] Peterborough City Hosp, Peterborough, Cambs, England
[3] Nottingham Univ Hosp, Nottingham, England
[4] Cardiff Univ, Cardiff, S Glam, Wales
[5] Aarhus Univ, Aarhus, Denmark
[6] Skane Univ Hosp, Malmo, Sweden
[7] Bayer, Berlin, Germany
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-P2-03-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-03-02
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phosphatidylinositol-3-OH kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor α (ERα) via interaction between ERα and PI3K
    Sun, M
    Paciga, JE
    Feldman, RI
    Yuan, ZQ
    Coppola, D
    Lu, YY
    Shelley, SA
    Nicosia, SV
    Cheng, JQ
    CANCER RESEARCH, 2001, 61 (16) : 5985 - 5991
  • [22] AR and PI3K/AKT in Prostate Cancer: A Tale of Two Interconnected Pathways
    Tortorella, Elisabetta
    Giantulli, Sabrina
    Sciarra, Alessandro
    Silvestri, Ida
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (03)
  • [23] Activation of PI3K/AKT/mTOR pathway in ER plus breast cancer: Analysis of paired primary and metastatic tumor samples.
    Pacheco, Teresa R.
    Fernandes, Afonso C.
    Ali, Suhail M.
    Maia-Matos, Mario
    da Costa, Ana Lucia Gaspar Gomes
    Abreu, Catarina
    Alves, Antonio Teixeira
    Correia, Lurdes
    Lara, Jonathan F.
    Michaelson, Richard Alan
    Ferreira, Arlindo Rebelo
    Matias, Margarida
    Leitzel, Kim
    Lipton, Allan
    Costa, Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [24] Perfluoroalkyl substances promote breast cancer progression via ERα and GPER mediated PI3K/Akt and MAPK/Erk signaling pathways
    Liu, Qianfeng
    Liu, Yongzhe
    Li, Xiaoyu
    Wang, Dan
    Zhang, Ai
    Pang, Jing
    He, Jiayu
    Chen, Xi
    Tang, Nai-jun
    ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY, 2023, 258
  • [25] Targeting PI3K overcomes in vivo resistance to everolimus in estrogen receptor (ER plus ) breast cancer
    O'Brien, N. A.
    Tong, L.
    Ayala, R.
    Issakhanian, S.
    McDonald, K.
    Hurvitz, S. A.
    DiTomaso, E.
    Linnartz, R.
    Finn, R. S.
    Hirawat, S.
    Slamon, D. J.
    CANCER RESEARCH, 2013, 73
  • [26] Inhibiting the expression of STARD3 induced apoptosis via the inactivation of PI3K/AKT/mTOR pathway on ER+ breast cancer
    Li, Ping
    Zhang, Zhou
    Lv, Hui
    Sun, Ping
    TISSUE & CELL, 2022, 79
  • [27] Incidence of oncogenes in PI3K/AKT and MAPK signaling pathways in breast cancer
    Cejalvo, J. M.
    Perez Fidalgo, J. A.
    Bermejo, B.
    Ibarrola-Villaba, M.
    Burgues, O.
    Ribas, G.
    Martinez, M. T.
    Lluch-Hernandez, A.
    ANNALS OF ONCOLOGY, 2015, 26
  • [28] Co-expression of estrogen receptor (ER), progesterone receptor (PR), and Ki67 in a single breast cancer cell indicates a favorable prognosis in ER-positive breast cancer
    Ueno, Takayuki
    Horii, Rie
    Matsumoto, Hiroshi
    Ono, Makiko
    Maeshima, Yurina
    Nitta, Hiroaki
    CANCER RESEARCH, 2024, 84 (09)
  • [29] PI3K-based molecular signatures link high PI3K pathway activity with low ER levels in ER+ breast cancer
    Sanchez, Alex
    Villanueva, Josep
    EXPERT REVIEW OF PROTEOMICS, 2010, 7 (06) : 819 - 821
  • [30] A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer
    Hadad, Sirwan M.
    Jordan, Lee B.
    Roy, Pankaj G.
    Purdie, Colin A.
    Iwamoto, Takayuki
    Pusztai, Lajos
    Moulder-Thompson, Stacy L.
    Thompson, Alastair M.
    BMC CANCER, 2016, 16
12345